Platelet-derived TLT-1 promotes tumor progression by suppressing CD8+ T cells
Authors:
- Tarun TyagiTTTarun Tyagi
- Kanika JainKJKanika Jain
- Timur O. YarovinskyTYTimur O. Yarovinsky
- Michael ChiorazziMCMichael Chiorazzi
- Jing DuJDJing Du
- Cecilia CastroCCCecilia Castro
- Jules GriffinJGJules Griffin
- Asawari KordeAKAsawari Korde
- Kathleen A. MartinKMKathleen A. Martin
- Shervin S. TakyarSTShervin S. Takyar
- Richard A. FlavellRFRichard A. Flavell
- Abhijit A. PatelAPAbhijit A. Patel
Open Access
- 28 October 2022
- journal article
- research article
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 220 (1)
Abstract
Current understanding of tumor immunosuppressive mechanisms forms the basis for modern day immunotherapies. Immunoregulatory role of platelets in cancer remains largely elusive. Platelets from non-small cell lung cancer (NSCLC) patients revealed a distinct activation phenotype. TREM-like transcript 1 (TLT-1), a platelet protein, was increased along with enhanced extracellular release from NSCLC platelets. The increased platelet TLT-1 was also evident in humanized mice with patient-derived tumors. In immunocompetent mice with syngeneic tumors, TLT-1 binding to T cells, in vivo, led to suppression of CD8 T cells, promoting tumor growth. We identified direct interaction between TLT-1 and CD3ε on T cells, implicating the NF-κB pathway in CD8 T cell suppression. Anti–TLT-1 antibody rescued patients’ T cells from platelet-induced suppression ex vivo and reduced tumors in mice in vivo. Clinically, higher TLT-1 correlated with reduced survival of NSCLC patients. Our findings thus identify TLT-1 as a platelet-derived immunosuppressor that suppresses CD8 T cells and demonstrate its therapeutic and prognostic significance in cancer.Keywords
Funding Information
- National Heart, Lung, and Blood Institute (RO1-HL122815, RO1-HL115247, RO1-HL150515)
This publication has 108 references indexed in Scilit:
- Activator protein 1 suppresses antitumor T-cell function via the induction of programmed death 1Proceedings of the National Academy of Sciences, 2012
- Paraneoplastic Thrombocytosis in Ovarian CancerNew England Journal of Medicine, 2012
- Chemokine receptor CXCR3 facilitates CD8+ T cell differentiation into short-lived effector cells leading to memory degenerationJournal of Experimental Medicine, 2011
- Transduction of Tumor-Specific T Cells with CXCR2 Chemokine Receptor Improves Migration to Tumor and Antitumor Immune ResponsesClinical Cancer Research, 2010
- Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanomaJournal of Clinical Investigation, 2010
- Existence of a microRNA pathway in anucleate plateletsNature Structural & Molecular Biology, 2009
- TREM-like transcript-1 protects against inflammation-associated hemorrhage by facilitating platelet aggregation in mice and humansJournal of Clinical Investigation, 2009
- A Primary Xenograft Model of Small-Cell Lung Cancer Reveals Irreversible Changes in Gene Expression Imposed by CultureIn vitroCancer Research, 2009
- A Comprehensive Proteomics and Genomics Analysis Reveals Novel Transmembrane Proteins in Human Platelets and Mouse Megakaryocytes Including G6b-B, a Novel Immunoreceptor Tyrosine-based Inhibitory Motif ProteinMolecular & Cellular Proteomics, 2007
- B16 as a Mouse Model for Human MelanomaCurrent Protocols in Immunology, 2000